Caremark RX (CMX)

STRONG BUY
An excellent entry point. They are now the biggest company in the institutional pharmacy space in Canada. They supply medication to long term care facilities. They have 23% of the market share in Canada. They only really have one competitor, Shoppers Drugmart, who are really focused on retail customers. The stock is really cheap here and a long runway ahead.
TOP PICK
Pharmacy Benefit Manager. Manage drug plans of big companies. Dropped from $60 in September. Caused by Wal-Mart’s $4 generic program, which he thinks is a non-issue. Good value.
BUY
Infrastructure is a big part of his investment process, so concrete is important. Stock is down a bit because of rumours of them making another acquisition. If that happens, the stock will probably stay flat and possibly drop a bit.
TOP PICK
Will benefit from the increasing trend towards mail order subscription. Will also be increasing some generics. Could propel their earnings up 20% in the foreseeable future. Good price.
TOP PICK
TOP PICK
Health care is going to be an area of opportunity this year. One of the largest pharmacy benefit management in the country. Should see earnings growth explode.
TOP PICK
Very profitable. Good price.
Showing 1 to 7 of 7 entries
  • «
  • 1
  • »

Caremark RX (CMX) Frequently Asked Questions

What is Caremark RX stock symbol?

Caremark RX is a OTC stock, trading under the symbol CMX (previously CMX-N on Stockchase) on the (). It is usually referred to as or CMX

Is Caremark RX a buy or a sell?

In the last year, there was no coverage of Caremark RX published on Stockchase.

Is Caremark RX a good investment or a top pick?

Caremark RX was recommended as a Top Pick by Brendan Kyne on 2003-01-20. Read the latest stock experts ratings for Caremark RX.

Why is Caremark RX stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.

Is Caremark RX worth watching?

In the last year, there was no coverage of Caremark RX published on Stockchase.